VINCREX Drug Patent Profile
✉ Email this page to a colleague
When do Vincrex patents expire, and when can generic versions of Vincrex launch?
Vincrex is a drug marketed by Bristol Myers Squibb and is included in one NDA.
The generic ingredient in VINCREX is vincristine sulfate. There are thirteen drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the vincristine sulfate profile page.
Summary for VINCREX
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 42 |
Clinical Trials: | 87 |
Patent Applications: | 3,724 |
Formulation / Manufacturing: | see details |
DailyMed Link: | VINCREX at DailyMed |
Recent Clinical Trials for VINCREX
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
City of Hope Medical Center | Phase 1 |
Yazeed Sawalha | Phase 1 |
National Cancer Institute (NCI) | Early Phase 1 |
Anatomical Therapeutic Chemical (ATC) Classes for VINCREX
US Patents and Regulatory Information for VINCREX
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Bristol Myers Squibb | VINCREX | vincristine sulfate | INJECTABLE;INJECTION | 070867-001 | Jul 12, 1988 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |